Cargando…

Assessment of functioning in patients with schizophrenia and schizoaffective disorder with the Mini-ICF-APP: a validation study in Italy

BACKGROUND: The aim of the study was to evaluate validity of the Italian Mini-ICF-APP (Mini-ICF Rating for Limitations of Activities and Participation in Psychological Disorders) in schizophrenia and related disorders. METHODS: 74 outpatients affected by schizophrenia or schizoaffective disorders at...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pinna, Federica, Fiorillo, Andrea, Tusconi, Massimo, Guiso, Beatrice, Carpiniello, Bernardo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4628277/ https://www.ncbi.nlm.nih.gov/pubmed/26526168 http://dx.doi.org/10.1186/s13033-015-0030-x

Ejemplares similares

Criteria for symptom remission revisited: a study of patients affected by schizophrenia and schizoaffective disorders
por: Pinna, Federica, et al.
Publicado: (2013)

Clinical Global Impression-severity score as a reliable measure for routine evaluation of remission in schizophrenia and schizoaffective disorders
por: Pinna, Federica, et al.
Publicado: (2015)

Gender Differences in Remission and Recovery of Schizophrenic and Schizoaffective Patients: Preliminary Results of a Prospective Cohort Study
por: Carpiniello, Bernardo, et al.
Publicado: (2012)

Psychiatry during the Covid-19 pandemic: a survey on mental health departments in Italy
por: Carpiniello, Bernardo, et al.
Publicado: (2020)

Assessing the severity of functional impairment of psychiatric disorders: equipercentile linking the mini-ICF-APP and CGI
por: Egger, Stephan T., et al.
Publicado: (2019)

Alcohol Use Disorder and Schizophrenia or Schizoaffective Disorder
por: Archibald, Luke, et al.
Publicado: (2019)

Critical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophrenia
por: Carpiniello, Bernardo, et al.
Publicado: (2016)

Enhancing Medication Adherence Among Patients With Schizophrenia and Schizoaffective Disorder: Mobile App Intervention Study
por: Al Dameery, Khloud, et al.
Publicado: (2023)

Neurophysiological Distinction between Schizophrenia and Schizoaffective Disorder
por: Mathalon, Daniel H., et al.
Publicado: (2010)

One-year follow-up of functional impairment in inpatients with mood and anxiety disorders – Potentials of the Mini-ICF-APP
por: Susanne, Jaeger, et al.
Publicado: (2022)

Efficacy and tolerability of Aripiprazole in Patients with Schizophrenia & Schizoaffective Disorders
por: Andrade, Chittaranjan
Publicado: (2004)

Efficacy and Tolerability of Aripiprazole in Patients with Schizophrenia & Schizoaffective Disorders
por: Chavda, R.K., et al.
Publicado: (2004)

Measuring Emotional Awareness in Patients With Schizophrenia and Schizoaffective Disorders
por: Maaßen, Eva, et al.
Publicado: (2021)

The Role of Gut Microbiota in the High-Risk Construct of Severe Mental Disorders: A Mini Review
por: Sani, Gabriele, et al.
Publicado: (2021)

Predominant Polarity and Polarity Index of Maintenance Treatments for Bipolar Disorder: A Validation Study in a Large Naturalistic Sample in Italy
por: Albert, Umberto, et al.
Publicado: (2021)

Correction: One-year follow-up of functional impairment in inpatients with mood and anxiety disorders – Potentials of the Mini-ICF-APP
por: Jaeger, Susanne, et al.
Publicado: (2022)

Stigma towards patients with schizophrenia and other mental disorders: Challenges and interventions in Italy
por: Carpiniello, B.
Publicado: (2021)

Trauma and Posttraumatic Stress Disorder (PTSD) in Patients with Schizophrenia or Schizoaffective Disorder
por: Lommen, Miriam J. J., et al.
Publicado: (2009)

Brain structural changes in schizoaffective disorder compared to schizophrenia and bipolar disorder
por: Amann, B. L., et al.
Publicado: (2015)

Impairment in delay discounting in schizophrenia and schizoaffective disorder but not primary mood disorders
por: Brown, Hannah E., et al.
Publicado: (2018)

Cardiovascular Risk for Patients With and Without Schizophrenia, Schizoaffective Disorder, or Bipolar Disorder
por: Rossom, Rebecca C., et al.
Publicado: (2022)

Converging Evidence Points to BDNF as Biomarker of Depressive Symptoms in Schizophrenia-Spectrum Disorders
por: Manchia, Mirko, et al.
Publicado: (2022)

The continuing story of schizophrenia and schizoaffective disorder: One condition or two?
por: Hartman, Leah I., et al.
Publicado: (2019)

Religious Coping Strategies for Religious Patients with Schizophrenia and Schizoaffective Disorder
por: Gedevani, E., et al.
Publicado: (2022)

The use of technologies and social media in patients with schizophrenia and schizoaffective disorder
por: Elleuch, O., et al.
Publicado: (2022)

Clinical factors affecting functioning in patients with schizophrenia or schizoaffective disorder
por: Neily, C., et al.
Publicado: (2022)

The assessment of capacity limitations in psychiatric work disability evaluations by the social functioning scale Mini-ICF-APP
por: Rosburg, Timm, et al.
Publicado: (2021)

Alexithymia in eating disorders: therapeutic implications
por: Pinna, Federica, et al.
Publicado: (2014)

Editorial: Case reports in schizophrenia and psychotic disorders
por: Tusconi, Massimo, et al.
Publicado: (2023)

microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder
por: Perkins, Diana O, et al.
Publicado: (2007)

Social function in schizophrenia and schizoaffective disorder: Associations with personality, symptoms and neurocognition
por: Lysaker, Paul H, et al.
Publicado: (2004)

Blonanserin-induced Mood Alteration in Schizophrenia and Schizoaffective Disorder: Two Cases
por: Min, Aran, et al.
Publicado: (2013)

Distinctive transcriptome alterations of prefrontal pyramidal neurons in schizophrenia and schizoaffective disorder
por: Arion, Dominique, et al.
Publicado: (2015)

The Effectiveness of Cross-Tapering Switching to Ziprasidone in Patients with Schizophrenia or Schizoaffective Disorder
por: Ko, Young-Hoon, et al.
Publicado: (2014)

Evidence for Distinguishable Treatment Costs among Paranoid Schizophrenia and Schizoaffective Disorder
por: Hirjak, Dusan, et al.
Publicado: (2016)

Study of the Effect of Memantine on Negative Sign in Patients with Schizophrenia and Schizoaffective Disorders
por: Tavakoli-Ardakani, Maria, et al.
Publicado: (2018)

Risk of readmission in patients with schizophrenia and schizoaffective disorder newly prescribed clozapine
por: Kesserwani, Jad, et al.
Publicado: (2019)

Social and Neurocognitive Deficits in Remitted Patients with Schizophrenia, Schizoaffective and Bipolar Disorder
por: Dehelean, Liana, et al.
Publicado: (2021)

Testing the hypothesis of subtypes of nonadherence in schizophrenia and schizoaffective disorder: A prospective study
por: Vega, Dulcinea, et al.
Publicado: (2020)

Reaction Time and Visual Memory in Connection with Alcohol Use in Schizophrenia and Schizoaffective Disorder
por: Mazumder, Atiqul Haq, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fterdrnecuarnkrghas0rkd6uj